No brainer for BrainZ
08 October, 2008 by Dylan Bushell-EmblingUS company Natus is after NZ’s BrainZ
More supply for AtCor
08 October, 2008 by Dylan Bushell-EmblingAtCor wins supply contract for SphygmoCor
No shock for USCOM
08 October, 2008 by Dylan Bushell-EmblingUSCOM improves paediatric septic shock management
Half-dose for Halcygen
07 October, 2008 by Dylan Bushell-EmblingHalcygen completes first required IND trial
PolyNovo trade agreed
02 October, 2008 by Dylan Bushell-EmblingXceed and Metabolic trade PolyNovo Biomaterials
Alchemia banks on 2010
02 October, 2008 by Dylan Bushell-EmblingAlchemia registers loss, expects to be in profit in 2010
Profile: the sense in Antisense
01 October, 2008 by Kate McDonaldThe antisense concept has been around for 30 years and now therapies are on the market and in the clinic, including a recently reported Phase IIa trial by Melbourne company Antisense Therapeutics.
Arana files IND
30 September, 2008 by Dylan Bushell-EmblingArana files IND application for rheumatoid arthritis candidate
Profile: tending the tendons by tissue repair
29 September, 2008 by Matt RodgersWestern Australian company Orthocell is pioneering biological therapies to repair and regenerate damaged tendons and ligaments.
Next step for Xenome
25 September, 2008 by Staff WritersXenome starts Phase II for acute post-operative pain
No alternative for Phosphagenics
24 September, 2008 by Dylan Bushell-EmblingPhosphagenics to delist from AIM, starts Phase I for delivery system
Bridge crossed by HeartWare
23 September, 2008 by Dylan Bushell-EmblingHeartWare gets FDA approval for investigational device
Antibody inflames Arana
23 September, 2008 by Dylan Bushell-EmblingArana develops new anti-inflammatory antibody candidate, prepares for clinic
